Table 2: Number and percentage of RA patients presenting ILD under anti-TNFα treatment.

Total no. of RA patientsPatients developing ILD References
anti-TNFα N/%Infliximab N/%Etanercept N/%Adalimumab N/%

10.649299 (2.8%)UNUNUNDixon et al., 2010 [26]

13.89477(0.6%)UN77 (0.6%)UNKoike et al., 2011 [27]

5.00025(0.5%)UN25 (0.5%)UNTakeuchi et al., 2008 [28]

ILD: interstitial lung disease; UN: unavailable.